Table 1. Baseline characteristics of patients at diagnosis and last follow-up.
Patients characteristics (n =101) | |
---|---|
Age at diagnosis | 64 (42–87) |
Male | 69 (68.3%) |
Diagnosis | |
MBL* | 6 (5.9%) |
CLL | 95 (94.1%) |
Binet stage** (n =90) | |
A | 57 (63.3%) |
B | 23 (25.6%) |
C | 10 (11.1%) |
B-symptoms (n = 67) | 6 (9%) |
Adenopathies (n = 71) | 37 (52.1%) |
Splenomegaly (n =68) | 12 (17.6%) |
Hepatomegaly (n =68) | 6 (8.8%) |
Absolute white blood cell count (× 109/L) (n = 71) | 20 (3.8–372) |
Absolute lymphocyte count (× 109/L) (n =68) | 15 (1–369) |
Hemoglobin (g/dL) (n = 68) | 13.8 (7–18) |
Platelets (×109/L) (n = 68) | 196 (2–356) |
Lactate dehydrogenase (IU/L) (n = 64) | 335 (180–959) |
Beta-2 microglobulin (mg/L) (n = 59) | 2.4 (1–8.4) |
Unmutated IGHV (n =32) | 27 (84.4%) |
Mutated NOTCH1 (n = 19) | 2 (10.5%) |
Last follow-up | |
Treated patients (n =97) | 81 (83.5%) |
Time to first treatment (months, 95% CI) (n = 96) | 23 (14–33) |
Deaths | 66 (65.3%) |
Overall survival (months, 95% CI) (n = 99) | 88 (67–108) |
Follow-up (months) | 62 (0–201) |
Values are given as median (range) or number (%). Hemoglobin is expressed as mean (range).
Although 6 patients were diagnosed as MBL (monoclonal B-cell lymphocytosis), all of them had already progressed to CLL at the time of study.
Some centers only provided information regarding the Binet stage without the physical examination and the analytical parameters.